Results 151 to 160 of about 8,073 (181)
Some of the next articles are maybe not open access.

Patterns of Clonal Evolution in Ph’-Positive Chronic Myelogenous Leukemia (CML) during Chronic Phase: Overall Incidence, Type, Multiplicity, Development Time, Effect on Subsequent Genetic Instability, Sokal Risk, Type of bcr/abl Transcript and Hematological Evolution.

Blood, 2006
Abstract Fifty-two kariotypic abnormalities additional to Philadelphia chromosome (Ph’) were documented at the time of diagnosis or during the course of the disease in 114 CML patients. Five were evaluated only once at the time of diagnosis, while 109 were repeatedly studied overtime during a median period of 138 (1–275)months.
Luzi D   +11 more
openaire   +3 more sources

Closely Related BCR/ABL Oncogenes Are Associated with the Distinctive Clinical Biologies of Philadelphia Chromosome Positive Chronic Myelogenous and Acute Lymphocytic Leukemia

1988
The study of oncogene activation in naturally occurring human leukemias provides a useful approach to define the range of growth regulatory mechanisms used by hematopoietic stem cells. Recent analysis of the structural changes created by the Philadelphia chromosome translocation [t(9;22) — (q34;q11)] shows that two alternative regions of the BCR gene ...
openaire   +3 more sources

[Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008
To investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).By using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR).
Ya-zhen, Qin   +10 more
openaire   +1 more source

[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].

Der Pathologe, 2005
In chronic myeloid leukemia following therapy with Imatinib (STI571) hematologic and cytogenetic response is associated with conspicuous changes of bone marrow morphology. However, it is not known to which extent these alterations are accompanied by a loss of the bcr/abl translocation. To study regression of the leukemic cell population we recruited 14
J, Thiele   +10 more
openaire   +1 more source

[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].

Gan to kagaku ryoho. Cancer & chemotherapy, 2003
A 71-year-old man with chronic myelogenous leukemia received interferon therapy for 21 months, but did not have complete cytogenetic response. Imatinib was then added to the former therapy. Imatinib was prescribed for only 12 days and discontinued because of severe erythema.
Atsushi, Ajima   +4 more
openaire   +1 more source

Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

Ca-A Cancer Journal for Clinicians, 2021
Amila K Nanayakkara   +2 more
exaly  

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Ciara C O’sullivan   +2 more
exaly  

Home - About - Disclaimer - Privacy